A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS

被引：0
|
作者：
Guadalupi, V. [1 ]
Giganti, M. O. [1 ]
Testa, I. [1 ]
Villa, S. [1 ]
Nicolai, N. [1 ]
Biasoni, D. [1 ]
Salvioni, R. [1 ]
Valdagni, R. [1 ]
Bajetta, E. [1 ]
Procopio, G. [1 ]
机构：
[1] Fondazione IRCCS, Ist Nazl Tumori, Milan, Italy
来源：
ANTICANCER RESEARCH | 2010年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
278
引用
收藏
页码：1536 / 1536
页数：1
相关论文
共 50 条
  • [31] Activity of abiraterone acetate in metastatic patients with castration-resistant prostate cancer (mCRPC) previously treated with ketoconazole: A prospective phase II study from the prostate cancer clinical trials consortium
    Kim, Won
    Wilton, John
    Zhang, Li
    Lin, Amy M.
    Fong, Lawrence
    Friedlander, Terence W.
    Hsieh, Andrew Caleb
    Aggarwal, Rahul Raj
    Rodvelt, Tammy J.
    Morse, Allison
    Bozeman, Jeffrey
    Weinberg, Vivian K.
    Molina, Arturo
    Mohler, James
    Fetterly, Gerald J.
    Szmulewitz, Russell Zelig
    Small, Eric Jay
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [32] DISEASE BURDEN OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN CHINA
    Ma, F. F.
    Liu, Q.
    Wang, J.
    Zhang, X. J.
    Yu, F.
    VALUE IN HEALTH, 2020, 23 : S451 - S452
  • [33] Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)
    Lee, Daniel J.
    Cha, Eugene K.
    Dubin, Justin M.
    Beltran, Himisha
    Chromecki, Thomas F.
    Fajkovic, Harun
    Scherr, Douglas S.
    Tagawa, Scott T.
    Shariat, Shahrokh F.
    BJU INTERNATIONAL, 2012, 109 (07) : 968 - +
  • [34] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Prospective evaluation of low-dose ketoconazole plus hydrocortisone (HC) in chemotherapy-pretreated castration-resistant prostate cancer (CRPC) patients.
    Lo, Ernest N.
    Beckett, Laurel A.
    Pan, Chong-Xian
    Robles, Daniel
    Suga, Jennifer Marie
    Sands, Jacob
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [36] Second line therapy for castration-resistant prostate cancer (CRPC)
    Molitor, B.
    Boergermann, C.
    UROLOGE, 2012, 51 (03): : 357 - 362
  • [37] Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone
    Ryan, C.
    Efstathiou, E.
    Smith, M.
    Taplin, M.
    Bubley, G.
    Logothetis, C.
    Kheoh, T.
    Haqq, C.
    Molina, A.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease
    Smith, D. C.
    Smith, M. R.
    Small, E. J.
    Sweeney, C.
    Kurzrock, R.
    Gordon, M. S.
    Vogelzang, N. J.
    Scheffold, C.
    Ballinger, M. D.
    Hussain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [39] Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)
    De Jager, R. L.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H.
    Earhart, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)
    Stein, M. N.
    Chen, Y.
    Hudes, G. R.
    Carducci, M. A.
    Tan, W.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345